Tempus AI/ML-enabled precision-medicine collaboration (expanded)
Clinical development Announcement
Disclosed: Verified: Partners: Tempus
GSK says it will work with Tempus, using Tempus's AI/ML capability and de-identified patient data, to improve clinical trial design, speed up enrolment and identify drug targets. GSK made a $70 million initial payment.
$70 million initial payment company-reported
Source
Company Archive pending